Current Report Filing (8-k)
22 March 2017 - 7:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2017
CONATUS PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
|
001-36003
|
|
20-3183915
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
16745 West Bernardo Drive, Suite 200
San Diego, CA
|
|
92127
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (858)
376-2600
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
|
Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On March 16, 2017, the board of directors of Conatus Pharmaceuticals
Inc. (the “Company”) appointed Steven J. Mento, Ph.D. as the Company’s acting Principal Financial Officer and
appointed Michelle L. Vandertie as the Company’s acting Principal Accounting Officer, each to be effective on March 31, 2017
upon the effectiveness of the previously announced resignation of Charles J. Cashion, the Company’s Senior Vice President,
Finance, Chief Financial Officer and Secretary. Dr. Mento will continue to serve as the Company’s President and Chief Executive
Officer and be compensated pursuant to his existing employment agreement with the Company. Ms. Vandertie will continue to serve
as the Company’s Vice President, Finance and be compensated pursuant to her existing employment agreement with the Company.
Ms. Vandertie, age 53, has served as the Company’s Vice President,
Finance since March 2016. Ms. Vandertie served as the Company’s Controller from October 2007 through March 2016. From January
2007 through October 2007, Ms. Vandertie served as an accounting consultant for the Company. Ms. Vandertie has held several management
level positions in both private and public companies and served as an auditor with Ernst & Young LLP from 1987 to 1990. Ms.
Vandertie received her bachelor’s degree from the University of Northern Colorado.
The Company entered into an employment agreement (the “Employment
Agreement”) with Ms. Vandertie, dated March 24, 2016, pursuant to which she currently receives an annual base salary of $245,623,
which amount is subject to annual review by and at the sole discretion of the Company’s board of directors or its designee.
Ms. Vandertie will also be eligible to earn an annual cash performance bonus equal to up to 30% of her then-current annual base
salary. The annual cash performance bonus will be based on her and/or the Company’s attainment of financial or other operating
criteria established by the Company’s board of directors or its designee, as determined by the Company’s board of directors
or its designee.
Pursuant to the Employment Agreement, if the Company terminates
Ms. Vandertie’s employment without cause (as defined in the Employment Agreement) or she resigns for good reason (as defined
in the Employment Agreement), she will be entitled to the following payments and benefits: (1) her fully earned but unpaid base
salary through the date of termination at the rate then in effect, plus all other amounts under any compensation plan or practice
to which she is entitled; (2) a lump sum cash payment in an amount equal to her monthly base salary as in effect immediately prior
to the date of termination for the six-month period following the date of termination; and (3) continuation of health benefits
for a period of six months following the date of termination.
The Employment Agreement provides that Ms. Vandertie’s stock
awards will immediately vest and become exercisable: (1) in the event of a change in control (as defined in the Employment Agreement),
the vesting of her stock awards will be automatically accelerated as to the number of stock awards that would vest over the 24-month
period following the date of such change in control; and (2) in the event her employment is terminated by the Company other than
for cause or by her for good reason, as to the number of stock awards that would have vested over the six-month period following
termination had she remained continuously employed by the Company during such period.
The foregoing description the Employment Agreement does not purport
to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, which is filed herewith
as Exhibit 10.1 and is incorporated herein by reference.
There are no family relationships between Ms. Vandertie and any
director or executive officer of the Company, and she has no direct or indirect material interest in any transaction required to
be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 9.01
|
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit No.
|
Description
|
|
|
10.1
|
Employment Agreement, dated March 24, 2016, between Conatus Pharmaceuticals
Inc. and Michelle L. Vandertie.
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 21, 2017
|
|
CONATUS PHARMACEUTICALS INC.
|
|
|
|
|
|
By:
|
/s/ Steven J. Mento, Ph.D.
|
|
|
Name:
|
Steven J. Mento, Ph.D.
|
|
|
Title:
|
President & Chief
Executive Officer
|
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to May 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Conatus Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Conatus Pharmaceuticals Inc. News Articles